|Bid||9.10 x 1200|
|Ask||13.00 x 1000|
|Day's Range||10.69 - 11.60|
|52 Week Range||9.00 - 27.50|
|Beta (3Y Monthly)||3.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.71|
Hemophilia B is a rare, genetic bleeding disorder caused by a lack of the factor IX (FIX) protein, which is necessary for normal blood clotting. SB-FIX uses Sangamo's proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a corrective copy of the F9 gene, which controls the production of FIX.
Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
The direct benefit for Sangamo Therapeutics Inc (NASDAQ:SGMO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
RICHMOND, Calif. and VALBONNE, France, Dec. 3, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. "The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development," said Sandy Macrae, CEO of Sangamo. In 2019, Sangamo expects to submit a clinical trial authorization application (CTA) in Europe for TxCell's first CAR-Treg investigational product candidate for solid organ transplant.
In November, of the total eight analysts covering Sangamo Therapeutics (SGMO), five have given the stock a “buy” or higher rating and three analysts have given it a “hold” rating. The mean rating for Sangamo Therapeutics stock is 2.0 with a target price of $22.71, implying an upside potential of 90.5% over the closing price of $11.92 on November 29.
Sangamo Therapeutics (SGMO) focuses on developing and bringing to market novel genomic therapies. Its genome editing and gene regulation technology platform is enabled by engineering transcription factors called zinc finger DNA-binding proteins, which can increase or decrease gene expression or gene regulation.
Sangamo Therapeutics (SGMO) incurred general and administrative expenses of $10.99 million in the third quarter of 2018, compared with $6.42 million in the third quarter of 2017. The fiscal 2018 research and development expenses for peers Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) are expected at $3.52 billion, $2.48 billion, and $3.71 billion, respectively. Sangamo Therapeutics’ net interest and other income grew from $681,000 in the third quarter of 2017 to $3.4 million in the latest quarter.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Sangamo is developing innovative gene-editing programs for many devastating diseases, but a J.P. Morgan analyst called it a ‘show-me story from here.’
Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.
Sangamo Therapeutics Inc. shares dropped as much as 10% in Wednesday premarket trade before evening out to a 4.6% decline after the company was downgraded to "neutral" at J.P. Morgan, with analyst Eric Joseph citing "growing skepticism about the company's lead development programs and their potential for value creation over the foreseeable future." Joseph also cut the company's price target by nearly 70% to $11. (Company shares closed at $10.80 on Tuesday.) Sangamo is a buzzy biotechnology company that focuses on a type of cutting-edge gene editing that utilizes "zinc finger" proteins. But whether the company's SB-525 program for hemophilia A is working "continues to elude, now with indefinite timelines," Joseph said, questioning whether the company can beat further-along competitors like BioMarin Pharmaceutical Inc. and Spark Therapeutics Inc. . The analyst also had questions about the company's SB-913 program, being developed for a metabolic disorder called Hunter syndrome; early results from a trial were recently released to skepticism, causing Sangamo shares to plummet. "We do believe that the breadth of the pipeline offers several potential catalysts longer term (12-18 months), but with management credibility increasingly coming into play, net-net, we view SGMO as a show-me story from here," Joseph said. Sangamo shares have dropped 32.1% over the last three months, compared with a 3.5% decline in the S&P 500 .
CRISPR Therapeutics (CRSP) reported revenues of $563,000 in the third quarter—compared to $2.4 million in the third quarter of 2017. CRISPR Therapeutics reported net revenues of $3.0 million over the first nine months of 2018—compared to $8.7 million during the same period in 2017. CRISPR Therapeutics’ net revenues are mainly from collaborations undertaken by the company.
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.
Sangamo (SGMO) delivered earnings and revenue surprises of 0.00% and -41.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
RICHMOND, Calif., Nov. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today reported third quarter 2018 financial results and recent business highlights. "I'm pleased with our continued execution toward our vision to transform Sangamo into the premier genomic medicines company," said Sandy Macrae, CEO of Sangamo. In September, Sangamo presented 16-week clinical results from the first two cohorts of the Phase 1/2 CHAMPIONS Study evaluating SB-913 for Mucopolysaccharidosis Type II (MPS II), including dose-dependent reductions in glycosaminoglycans (GAGs) in the second cohort (1e13 vector genomes per kilogram of body weight, or vg/kg).
RICHMOND, Calif. , Nov. 6, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor conferences in November. ...